Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Key Points
Exploration for biomarkers for drugs that block immune checkpoints should be rationally conducted based on knowledge of the mechanism of action of the targeted pathway. The programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte associated antigen 4 (CTLA4) pathways are unique, and there are special considerations based on me...
Alternative Titles
Full title
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5381938
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5381938
Other Identifiers
ISSN
1474-175X
E-ISSN
1474-1768
DOI
10.1038/nrc.2016.36
